Author: Angamo, Mulugeta T.; Mohammed, Mohammed A.; Peterson, Gregory M.
Title: Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis Cord-id: 7vy4u073 Document date: 2021_7_31
ID: 7vy4u073
Snippet: PURPOSE: This review was aimed to synthesise the best available evidence on the effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19. METHOD: Randomised controlled trials (RCTs) and observational studies reporting the effectiveness and safety of remdesivir were searched via databases and other sources from December 2019 to December 2020. Two independent reviewers performed literature screening, data extraction and assessment of risk bias. Seven studies involving
Document: PURPOSE: This review was aimed to synthesise the best available evidence on the effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19. METHOD: Randomised controlled trials (RCTs) and observational studies reporting the effectiveness and safety of remdesivir were searched via databases and other sources from December 2019 to December 2020. Two independent reviewers performed literature screening, data extraction and assessment of risk bias. Seven studies involving 3686 patients were included. RESULTS: Treatment with remdesivir was associated with an increase in clinical recovery rate by 21% (RR 1.21; 95% CI 1.08–1.35) on day 7 and 29% (RR 1.29; 95% CI 1.22–1.37) on day 14. The likelihoods of requiring high-flow supplemental oxygen and invasive mechanical ventilation in the remdesivir group were lower than in the placebo group by 27% (RR 0.73; 95% CI 0.54–0.99) and 47% (RR 0.53; 95% CI 0.39–0.72), respectively. Remdesivir-treated patients showed a 39% (RR 0.61; 95% CI 0.46–0.79) reduction in the risk of mortality on day 14 compared to the control group; however, there was no significant difference on day 28. Serious adverse effects (SAEs) were significantly less common in patients treated with remdesivir, with an absolute risk difference of 6% (RD −0.06; 95% CI −0.09 to −0.03). CONCLUSION: Despite conditional recommendation against its use, remdesivir could still be effective in early clinical improvement; reduction of early mortality and avoiding high-flow supplemental oxygen and invasive mechanical ventilation among hospitalised COVID-19 patients. Remdesivir was also well tolerated without significant SAEs compared to placebo, yet available evidence from clinical studies support the need to conduct close monitoring. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-021-01671-0.
Search related documents:
Co phrase search for related documents- abstract title and acute kidney injury: 1
- abstract title and acute respiratory distress syndrome: 1
- abstract title and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- abstract title and lopinavir ritonavir: 1, 2
- abstract title and low likelihood: 1
- abstract title and low number: 1, 2, 3
- abstract title and low proportion: 1
- abstract title screen and acute respiratory syndrome: 1, 2
- acute kidney injury and loading dose: 1
- acute kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute kidney injury and low likelihood: 1
- acute kidney injury and low number: 1
- acute kidney injury and low requirement: 1
- acute kidney injury incidence and lopinavir ritonavir: 1, 2, 3, 4
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and low flow oxygen: 1, 2, 3
- acute respiratory distress syndrome and low likelihood: 1, 2
- acute respiratory distress syndrome and low number: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and low proportion: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date